Every material Form 8-K Avalo Therapeutics, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Avalo Therapeutics entered an at-the-market sales agreement with Jefferies LLC that lets it sell up to $200 million of common stock over time at its discretion, with a commission of up to 3.0% of gross proceeds. The same day, the company ended its prior at-the-market agreement with TD Cowen, effective immediately, so new share sales can only occur under the Jefferies arrangement. New share sales would add to the outstanding shares and could dilute existing shareholders.
Jefferies sales agreement covers up to $200,000,000 in aggregate offering price under a prospectus supplement dated November 5, 2026.
Company pays Jefferies a commission of up to 3.0% of gross proceeds from any shares sold.
The company is not obligated to sell any shares, and it may suspend or terminate the offering.
TD Cowen sales agreement, dated June 5, 2025, was terminated effective November 5, 2026.
Avalo Therapeutics reported a third-quarter 2026 net loss of $18.9 million, or $0.34 per share, down from $30.6 million, or $2.19 per share, a year earlier. The filing attributes the narrower loss mainly to a change in the fair value of a derivative liability, while operating expenses rose $4.2 million, and the company says its cash is expected to fund operations into 2029.
Net loss was $18.9 million for the quarter ended September 30, 2026, a decrease of $11.7 million from the prior-year quarter.
Total operating expenses rose $4.2 million to $23.4 million, led by research and development ($15.0 million) and general and administrative ($8.4 million) costs.
Cash, cash equivalents and investments were $462.8 million as of September 30, 2026, expected to fund operations into 2029.
Avalo expects FDA feedback on its abdakibart development plan by year-end 2026 and plans to start a Phase 3 program in the first half of 2027.
Avalo Therapeutics reported a second-quarter 2026 net loss of $36.4 million, up $15.6 million from a year earlier, as research and development and general and administrative expenses rose. The company reported $472.2 million in cash, cash equivalents and investments as of June 30, 2026, which it says should fund operations into 2029, and plans to start a Phase 3 trial of abdakibart in hidradenitis suppurativa in the first half of 2027.
Q2 2026 net loss was $36.4 million versus $20.8 million in Q2 2025; net loss per share was $0.83 versus $1.92, on 43,602,044 weighted average shares versus 10,829,760.
R&D expenses were $23.4 million, up $9.3 million, including a $10.0 million development milestone for abdakibart; G&A expenses were $8.1 million, up $2.9 million.
Cash, cash equivalents and investments were $472.2 million at June 30, 2026, with the company expecting runway into 2029.
Plans to initiate a registrational Phase 3 program for abdakibart in HS in the first half of 2027; AVTX-010 IND submission planned for the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Avalo Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →